Clinical Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects

Phase 2 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221239

Enrollment

Registered

2010-09-10

Start date

2010-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

investigational material(s) Generic name etc : BMS-690514 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects must have recurrent, metastatic or progressive NSCLC Pathologically confirmed NSCLC Previously received treatment with single agent Gefitinib or Erlotinib Any one of the following: - A tumor that harbors an EGFR mutation - Objective clinical benefit from treatment with Gefitinib or Erlotinib - Progression of NSCLC while on continuous treatment with gefitinib or erlotinib as noted by CT/MRI increase in disease within 3 months of study enrollment

Exclusion criteria

Exclusion criteria: - Symptomatic brain metastasis - Adequate organ function and performance status

Design outcomes

Primary

Measure	Time frame
- To estimate objective response rate of BMS-690514 in NSCLC subjects	—

Secondary

Measure	Time frame
- To estimate progression free survival of BMS-690514 - To evaluate safety and tolerability of BMS-690514	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026